timothy sykes logo
SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet Thumbnail
G Google News

SMMT Stock Jumps As AstraZeneca Backs Ivonescimab Bet

ELLIS HOBBS•UPDATED SEP. 29, 2026, 4:47 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Summit Therapeutics Inc. stocks have been trading up by 5.88 percent following upbeat sentiment on its latest clinical progress.

Key Takeaways Traders Need To Know

  • AstraZeneca is committing a $2B equity stake into Summit Therapeutics via convertible preferred stock at an implied $18.36 per share, plus a broad ivonescimab collaboration.
  • Late‑stage HARMONi and HARMONi‑2 data show ivonescimab improving overall survival versus chemo and pembrolizumab in lung cancer, supporting a filed BLA with a 2026/11/14 PDUFA date.
  • China’s HARMONi‑2 and HARMONi‑GI1 trials show ivonescimab beating pembrolizumab and durvalumab combos in advanced NSCLC and biliary tract cancer, widening the drug’s tumor footprint.
  • Jefferies upgraded SMMT to Buy and hiked its target to $25, leaning into upcoming HARMONi‑3 progression‑free survival data.
  • Shares of SMMT spiked roughly 15% in after‑hours trading on the AstraZeneca news, signaling strong trader appetite for the new partnership.

Candlestick Chart

Live Update At 16:46:55 EDT: On Tuesday, September 29, 2026 Summit Therapeutics Inc. stock [NASDAQ: SMMT] is trending up by 5.88%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SMMT is trading like a high‑beta biotech, and the chart backs that up. Over the last couple of weeks, Summit Therapeutics has swung between roughly $16 and $19, with the latest close near $16.39 after a volatile session that opened above $18.80 and flushed hard intraday. That kind of range says one thing to short‑term traders: this is a momentum vehicle, not a sleepy pharma.

Intraday, SMMT’s 5‑minute candles show heavy selling from the pre‑market highs near $19 down into the mid‑$16s, followed by tight consolidation between $16.30 and $16.60 into the close. For day traders, that screams “exhausted spike, watch for the next catalyst before chasing.”

More Breaking News

Fundamentally, Summit Therapeutics is still a classic development‑stage biotech. The latest quarterly numbers show about $238.6M in cash and cash equivalents, a very strong current ratio around 7, and minimal debt relative to equity. At the same time, SMMT is burning cash fast: operating cash flow was about ‑$93.1M for the quarter and net income was roughly ‑$231.8M, with no meaningful revenue. That mix — strong balance sheet, heavy burn, and a rich price‑to‑book near 19.8 — tells traders this story is almost entirely about future drug approvals and partnerships, not current earnings.

Why Traders Are Watching SMMT Momentum

Traders are zeroed in on SMMT because AstraZeneca just validated the entire Summit Therapeutics story with real money. The big pharma giant is putting $2B into SMMT through convertible preferred shares, paying an implied $18.36 per common share — a premium to where SMMT has been trading. When a heavyweight like AstraZeneca pays above‑market and also signs up for a broad clinical collaboration, momentum traders pay attention.

This deal is more than a headline. AstraZeneca will collaborate on ivonescimab across multiple tumor types, including combinations with its own antibody‑drug conjugates such as sonesitatug vedotin. In practical terms, SMMT now has a deep‑pocketed partner funding key combo trials, which stretches Summit Therapeutics’ cash runway and adds more “shots on goal” without matching dilution.

That’s exactly why SMMT shares jumped about 15% in after‑hours trading on 2026/09/28 when the deal hit the tape. The move confirmed that the market had been waiting for external validation of ivonescimab. For active traders, this kind of news‑driven spike often becomes a multi‑day trading theme, with dip‑buying, short traps, and sharp squeezes as new headlines and analyst notes roll in.

Underneath the deal, the clinical story around SMMT is also getting stronger. Updated Phase III HARMONi and HARMONi‑2 data show ivonescimab delivering statistically significant overall survival benefits versus both placebo plus chemotherapy and pembrolizumab, across Asian and Western lung cancer populations, with no new safety signals. Akeso’s China‑based HARMONi‑2 and HARMONi‑GI1 trials pushed the narrative further, showing ivonescimab outperforming pembrolizumab and durvalumab‑plus‑chemo regimens in NSCLC and biliary tract cancer. That breadth across tumors is why traders now see Summit Therapeutics less as a one‑off lung cancer bet and more as a platform oncology name.

Wall Street is starting to lean in as well. Jefferies upgraded SMMT from Hold to Buy and took its target from $15 to $25, explicitly flagging confidence ahead of HARMONi‑3 progression‑free survival data. When you have a premium‑priced AstraZeneca deal, late‑stage data wins, and a Street upgrade all lining up, you tend to get the type of momentum setup day traders hunt for.

Conclusion

SMMT is a textbook example of how biotech catalysts can flip a chart from range‑bound to explosive. Summit Therapeutics just locked in a $2B strategic investment from AstraZeneca at a premium valuation, plus a clinical partnership that shifts a big chunk of ivonescimab combo spending onto a global pharma balance sheet. For traders, that reduces financing overhang and tightens the link between SMMT’s tape and future clinical headlines.

At the same time, the Phase III data stack around ivonescimab keeps growing. Between HARMONi, HARMONi‑2, and HARMONi‑GI1, Summit Therapeutics and partner Akeso have shown meaningful survival and response benefits versus current standards like chemo, pembrolizumab, and durvalumab‑based regimens. Add a defined U.S. PDUFA date on 2026/11/14, and SMMT now trades around a clear regulatory timeline.

None of this guarantees how SMMT will perform from here. Biotech history is full of sharp spikes followed by brutal fade‑outs. That’s why, in the words often echoed in the Sykes community, “cut losses quickly — hope is not a strategy.” As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”. For active traders studying SMMT, the edge comes from tracking the data, watching the volume, and treating every move as a trade, not a promise. This coverage is for educational and research purposes only, to help you think through the setup — not to tell you what to do.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”